(Part one of a four-part series)

Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to major innovative heights.

Psychedelic science is growing in terms of treatment specificity, as each novel or classical compound targets and aims to ameliorate or cure particular health conditions. Towards this goal, researchers are working to develop substances that hold on to the benefits and let go of the side effects of original, "first-generation" psychedelic substances.

This is what a common definition of next-generation psychedelics looks like.

In order to help familiarize our readers with this new field, Benzinga interviewed the CEO and regulatory development advisor of an Israeli-based psychedelics company, which is researching addiction treatment with a molecule called MEAI.

Clearmind Medicine …

Full story available on Benzinga.com